Form 4: Evoke Pharma CEO Sells Shares Post-Merger

Evoke Pharma Inc.'s CEO, Matthew J. D'Onofrio, reported the disposition of common stock and stock options following the company's acquisition by QOL Medical, LLC.

Summary

• Evoke Pharma Inc. completed its merger with QOL Medical, LLC and its wholly-owned subsidiary, QOL-EOS Merger Sub, Inc., effective December 17, 2025.
• The acquisition was executed through a tender offer where all outstanding shares of Evoke Pharma Common Stock were acquired for $11.00 per share in cash.
• Matthew J. D'Onofrio, Chief Executive Officer and Director, disposed of 15,509 shares of Common Stock on December 16, 2025, as part of the tender offer.
• Additionally, Mr. D'Onofrio's stock options, totaling 64,840 options with an exercise price of $5.27 and 70,000 options with an exercise price of $4.45, were canceled and converted into a cash payment immediately prior to the merger's effective time on December 17, 2025.
• The cash payment for options was calculated as the aggregate number of shares underlying each option multiplied by the difference between the $11.00 Offer Price and the option's per share exercise price.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and tender offer, providing cash to shareholders and option holders, indicating a positive outcome for those holding Evoke Pharma securities. While the company ceases to be independent, the financial terms of the exit are favorable for investors.

Positives

• Shareholders received a cash payment of $11.00 per share for their common stock, providing liquidity and a defined return.
• Stock option holders, including the CEO, received cash payouts for their vested options, calculated based on the difference between the offer price and the exercise price, indicating a profitable exit for in-the-money options.

Negatives

• Evoke Pharma Inc. is no longer an independent publicly traded company, becoming a wholly-owned subsidiary of QOL Medical, LLC.

Future Outlook

Evoke Pharma Inc. is now a wholly-owned subsidiary of QOL Medical, LLC, and will no longer operate as an independent publicly traded entity. Its future operations and strategic direction will be determined by its new parent company.

Industry Context

This announcement reflects a specific corporate acquisition within the pharmaceutical sector, where a smaller, publicly traded company is acquired by a private entity. Such transactions are common for companies seeking to consolidate assets, expand product portfolios, or achieve operational synergies.

Stakeholder Impact

• Shareholders received a cash payment of $11.00 per share, providing a clear return on investment.
• Option holders received cash for their options, based on the difference between the offer price and their exercise price.
• Employees and management of Evoke Pharma Inc. are now part of the QOL Medical, LLC organization, with their roles and integration subject to the new parent company's plans.

Next Steps

• Evoke Pharma Inc. will continue as the surviving corporation and a wholly-owned subsidiary of QOL Medical, LLC.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Matthew J. D'Onofrio